Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C18H24NO4 |
| Molecular Weight | 318.3875 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 6 / 6 |
| E/Z Centers | 0 |
| Charge | 1 |
SHOW SMILES / InChI
SMILES
[H][C@@]12O[C@]1([H])[C@H]3C[C@H](C[C@@H]2[N+]3(C)C)OC(=O)[C@H](CO)C4=CC=CC=C4
InChI
InChIKey=LZCOQTDXKCNBEE-IKIFYQGPSA-N
InChI=1S/C18H24NO4/c1-19(2)14-8-12(9-15(19)17-16(14)23-17)22-18(21)13(10-20)11-6-4-3-5-7-11/h3-7,12-17,20H,8-10H2,1-2H3/q+1/t12-,13-,14-,15+,16-,17+/m1/s1
Methscopolamine bromide is an anticholinergic agent used along with other medications to treat peptic ulcers by reducing stomach acid secretion. Methscopolamine is also commonly used as a drying agent, to dry up post-nasal drip, in cold, irritable bowel syndrome and allergy medications. Methscopolamine binds to M1-M5 isoforms of muscarinic receptors.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL216 |
0.53 nM [Kd] | ||
Target ID: CHEMBL211 |
0.55 nM [Kd] | ||
Target ID: CHEMBL245 |
1.38 nM [Kd] | ||
Target ID: CHEMBL1821 |
0.44 nM [Kd] | ||
Target ID: CHEMBL2035 |
0.59 nM [Kd] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | PAMINE Approved UseMethscopolamine bromide is an anticholinergic agent which possesses most of the pharmacological actions of that drug class. These include reduction in volume and total acid content of gastric secretion, inhibition of gastrointestinal motility, inhibition of salivary excretion, dilation of the pupil and inhibition of accommodation with resulting blurring of vision. Large doses may result in tachycardia. Launch Date-5.27990391E11 |
|||
| Palliative | DALLERGY Approved UseThis product provides relief of the symptoms resulting from irritation of sinus, nasal, and upper respiratory tract tissue. Phenylephrine exerts a vasoconstrictive and decongestive action while chlorpheniramine maleate decreases the symptoms of watering eyes, post nasal drip, and sneezing. Methscopolamine nitrate further augments the antisecretory activity of this product. |
|||
| Palliative | DALLERGY Approved UseThis product provides relief of the symptoms resulting from irritation of sinus, nasal, and upper respiratory tract tissue. Phenylephrine exerts a vasoconstrictive and decongestive action while chlorpheniramine maleate decreases the symptoms of watering eyes, post nasal drip, and sneezing. Methscopolamine nitrate further augments the antisecretory activity of this product. |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Effect of cholingeric drugs on methadone-induced catalepsy and stereotypies in rats treated chronically with methadone. | 1976 Oct |
|
| Central cholinergic mechanisms in L-DOPA induced hyperactive urinary bladder of the rat. | 1982 |
|
| Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. | 1997 Jul |
|
| Subtype-selective positive cooperative interactions between brucine analogues and acetylcholine at muscarinic receptors: radioligand binding studies. | 1998 Mar |
|
| Interaction of neuromuscular blocking drugs with recombinant human m1-m5 muscarinic receptors expressed in Chinese hamster ovary cells. | 1998 Nov |
|
| Allosteric effects of four stereoisomers of a fused indole ring system with 3H-N-methylscopolamine and acetylcholine at M1-M4 muscarinic receptors. | 1999 |
|
| Allosteric interactions of staurosporine and other indolocarbazoles with N-[methyl-(3)H]scopolamine and acetylcholine at muscarinic receptor subtypes: identification of a second allosteric site. | 2000 Jul |
|
| A snake venom inhibitor to muscarinic acetylcholine receptor (mAChR): isolation and interaction with cloned human mAChR. | 2000 May 15 |
|
| Analogs of WIN 62,577 define a second allosteric site on muscarinic receptors. | 2002 Dec |
|
| Zebrafish M2 muscarinic acetylcholine receptor: cloning, pharmacological characterization, expression patterns and roles in embryonic bradycardia. | 2002 Nov |
|
| Bisquaternary dimers of strychnine and brucine. A new class of potent enhancers of antagonist binding to muscarinic M2 receptors. | 2003 Jun 12 |
|
| Pilocarpine-induced seizures in adult rats: monoamine content and muscarinic and dopaminergic receptor changes in the striatum. | 2003 Oct |
|
| Modifications in muscarinic, dopaminergic and serotonergic receptors concentrations in the hippocampus and striatum of epileptic rats. | 2005 Dec 5 |
|
| Asparagine, valine, and threonine in the third extracellular loop of muscarinic receptor have essential roles in the positive cooperativity of strychnine-like allosteric modulators. | 2005 May |
|
| Critical amino acid residues of the common allosteric site on the M2 muscarinic acetylcholine receptor: more similarities than differences between the structurally divergent agents gallamine and bis(ammonio)alkane-type hexamethylene-bis-[dimethyl-(3-phthalimidopropyl)ammonium]dibromide. | 2005 Sep |
|
| Interaction studies of multiple binding sites on m4 muscarinic acetylcholine receptors. | 2006 Aug |
|
| Allosteric site in M2 acetylcholine receptors: evidence for a major conformational change upon binding of an orthosteric agonist instead of an antagonist. | 2006 Jan |
|
| Allosteric interactions with muscarinic acetylcholine receptors: complex role of the conserved tryptophan M2422Trp in a critical cluster of amino acids for baseline affinity, subtype selectivity, and cooperativity. | 2006 Jul |
|
| Identification of various allosteric interaction sites on M1 muscarinic receptor using 125I-Met35-oxidized muscarinic toxin 7. | 2006 May |
|
| Attenuation of cocaine's reinforcing and discriminative stimulus effects via muscarinic M1 acetylcholine receptor stimulation. | 2010 Mar |
|
| Zinc oxide nanoparticle disruption of store-operated calcium entry in a muscarinic receptor signaling pathway. | 2010 Oct |
Patents
Sample Use Guides
The average dosage of Methscopolamine Bromide Tablets USP is 2.5 mg one-half hour before meals and 2.5 to 5 mg at bedtime. A starting dose of 12.5 mg daily will be clinically effective in most patients without the production of appreciable side effects.
Route of Administration:
Oral
In the standard assay, mAChR subtypes (20-30 fmol/tube) in particulate fractions of Sf9 cells were incubated with 4 to 4.2 nM [3H]NMS (methscopolamine) and different concentrations of muscarinic ligands in 20 mM K-phosphate buffer (pH 7). Bound [3H]NMS trapped on the filter was counted with a liquid scintillation counter.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
LIVERTOX |
621
Created by
admin on Fri Dec 15 15:57:41 UTC 2023 , Edited by admin on Fri Dec 15 15:57:41 UTC 2023
|
||
|
WHO-ATC |
S01FA03
Created by
admin on Fri Dec 15 15:57:41 UTC 2023 , Edited by admin on Fri Dec 15 15:57:41 UTC 2023
|
||
|
NDF-RT |
N0000175370
Created by
admin on Fri Dec 15 15:57:41 UTC 2023 , Edited by admin on Fri Dec 15 15:57:41 UTC 2023
|
||
|
WHO-ATC |
A03BB03
Created by
admin on Fri Dec 15 15:57:41 UTC 2023 , Edited by admin on Fri Dec 15 15:57:41 UTC 2023
|
||
|
WHO-VATC |
QS01FA03
Created by
admin on Fri Dec 15 15:57:41 UTC 2023 , Edited by admin on Fri Dec 15 15:57:41 UTC 2023
|
||
|
WHO-ATC |
A03CB01
Created by
admin on Fri Dec 15 15:57:41 UTC 2023 , Edited by admin on Fri Dec 15 15:57:41 UTC 2023
|
||
|
WHO-VATC |
QA03BB03
Created by
admin on Fri Dec 15 15:57:41 UTC 2023 , Edited by admin on Fri Dec 15 15:57:41 UTC 2023
|
||
|
WHO-VATC |
QA03CB01
Created by
admin on Fri Dec 15 15:57:41 UTC 2023 , Edited by admin on Fri Dec 15 15:57:41 UTC 2023
|
||
|
NCI_THESAURUS |
C29704
Created by
admin on Fri Dec 15 15:57:41 UTC 2023 , Edited by admin on Fri Dec 15 15:57:41 UTC 2023
|
||
|
NDF-RT |
N0000175574
Created by
admin on Fri Dec 15 15:57:41 UTC 2023 , Edited by admin on Fri Dec 15 15:57:41 UTC 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB32123
Created by
admin on Fri Dec 15 15:57:41 UTC 2023 , Edited by admin on Fri Dec 15 15:57:41 UTC 2023
|
PRIMARY | |||
|
DB11315
Created by
admin on Fri Dec 15 15:57:41 UTC 2023 , Edited by admin on Fri Dec 15 15:57:41 UTC 2023
|
PRIMARY | |||
|
13265-10-6
Created by
admin on Fri Dec 15 15:57:41 UTC 2023 , Edited by admin on Fri Dec 15 15:57:41 UTC 2023
|
PRIMARY | |||
|
100000124342
Created by
admin on Fri Dec 15 15:57:41 UTC 2023 , Edited by admin on Fri Dec 15 15:57:41 UTC 2023
|
PRIMARY | |||
|
D019832
Created by
admin on Fri Dec 15 15:57:41 UTC 2023 , Edited by admin on Fri Dec 15 15:57:41 UTC 2023
|
PRIMARY | |||
|
C76001
Created by
admin on Fri Dec 15 15:57:41 UTC 2023 , Edited by admin on Fri Dec 15 15:57:41 UTC 2023
|
PRIMARY | |||
|
1757
Created by
admin on Fri Dec 15 15:57:41 UTC 2023 , Edited by admin on Fri Dec 15 15:57:41 UTC 2023
|
PRIMARY | |||
|
VDR09VTQ8U
Created by
admin on Fri Dec 15 15:57:41 UTC 2023 , Edited by admin on Fri Dec 15 15:57:41 UTC 2023
|
PRIMARY | |||
|
5420
Created by
admin on Fri Dec 15 15:57:41 UTC 2023 , Edited by admin on Fri Dec 15 15:57:41 UTC 2023
|
PRIMARY | |||
|
Methscopolamine
Created by
admin on Fri Dec 15 15:57:41 UTC 2023 , Edited by admin on Fri Dec 15 15:57:41 UTC 2023
|
PRIMARY | |||
|
VDR09VTQ8U
Created by
admin on Fri Dec 15 15:57:41 UTC 2023 , Edited by admin on Fri Dec 15 15:57:41 UTC 2023
|
PRIMARY | |||
|
DTXSID0046931
Created by
admin on Fri Dec 15 15:57:41 UTC 2023 , Edited by admin on Fri Dec 15 15:57:41 UTC 2023
|
PRIMARY | |||
|
89785
Created by
admin on Fri Dec 15 15:57:41 UTC 2023 , Edited by admin on Fri Dec 15 15:57:41 UTC 2023
|
PRIMARY | RxNorm |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
